
Please contact the doctor's office to verify that your insurance is accepted.
Dr. Scandura received a B.S. in Electrical Engineering from Cornell Ithaca in 1987, and an MS in Biomedical Engineering at the University of Pennsylvania in 1992. He completed the MD/PhD program in Biochemistry at Temple University in 1997. His doctoral work investigating critical interactions between platelets and coagulation factors led to three first-authored papers in Biochemistry.
Following his residency in internal medicine-research track at Weill Medical College, New York Presbyterian Hospital from 1997-1999, Dr. Scandura did a Fellowship in Medical Oncology at Memorial Sloan-Kettering Cancer Center from 1999-2003. Dr. Scandura was appointed Instructor on the Leukemia Service...
Defining and predicting disease progression in myeloproliferative neoplasms: a proposed biomarker-driven approach.
Epigenetic Priming with Azacitidine Prior to Allogeneic Hematopoietic Stem Cell Transplantation for Myeloid Malignancies: A Phase II Study.
Between the classic hit and the modern sequel: transition dosing between peginterferon alfa-2a and ropeginterferon alfa-2b for myeloproliferative neoplasms.